ARPA‑H Funds $62.7M Push to Build Autonomous AI for Heart‑Failure Care

Overview

• ARPA‑H announced on Sept. 9 selections and initial funding for the ADVOCATE program, a four‑year, $62.7 million effort with about $33.7 million available in year one to develop an agentic clinical AI for cardiovascular care.
• Three companies—Atman Health, Tempus AI and UpDoc—were tapped to build patient‑facing AI agents while Stanford will build a supervisory safety system and Duke and Kaiser Permanente will lead multi‑site EHR integrations and real‑world deployments.
• UpDoc was named a lead performer with up to $9.2 million and listed Microsoft, OpenAI and NVIDIA as supporting partners, but its proposed agentic cardiovascular system is not FDA‑cleared despite the company’s prior FDA clearance for an insulin‑management product.
• The program requires independent verification and validation by Johns Hopkins APL, benchmarking against cardiologists, FDA Investigational Device Exemption trials, and expects a lead developer to submit an FDA authorization package within roughly 24 months.
• ARPA‑H frames the project as a response to cardiology access gaps—nearly half of U.S. counties lack a cardiologist—and projects possible large cost and care gains if the technology proves safe, though major technical, regulatory and integration hurdles remain.